Health News Releases

May 15, 10:02

Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19

Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus. lactis strain Plasma[1](L.lactis Plasma, a postbiotic), researched and developed by

May 14, 10:15

AOP Health Presents New Findings Regarding Consistent Hematologic Response of Patients With polycythaemia vera

AOP Health announced new results on ropeginterferon alfa-2b (BESREMi®) from its clinical study CONTINUATION-PV in patients with polycythaemia vera (PV), a rare blood cancer. Professor Heinz Gisslinger

May 12, 14:45

Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook

Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2022 (period ended March 31, 2023), delivering or exceeding management guidance, driven by the performance of its

May 12, 09:35

SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines

Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced it will provide its inactivated COVID-19 vaccine, CoronaVac®

May 11, 13:29

Oncocross Completes Phase 1 Global Clinical Trial of OC514, Treatment for Sarcopenia

Oncocross, a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and other rare muscular disease

May 10, 17:22

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight

Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose. The

May 10, 15:40

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerab

May 10, 14:50

Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor

Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-10

May 10, 11:30

Kenvue Announces Closing of Initial Public Offering

Kenvue Inc. (NYSE: KVUE) (“Kenvue”) the world’s largest pure-play consumer health company by revenue, today announced the closing of its initial public offering (“IPO”) of 198,734,444 shares of its co

May 10, 10:15

Four Analyses of Data for REBYOTA™ (fecal microbiota, live - jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023

Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week® (DDW 2023) for REBYOTA™ (fecal microbiota, live - jslm) a first-in-class single-

May 09, 16:55

Amicogen and Lysando: Novel Approach for the Treatment of Mastitis in Dairy Cows

Amicogen, a leading biotech company specializing in industrial enzyme production and drug development, has partnered with Lysando, an innovative biotech company with expertise in the development of an

May 09, 10:40

Cambridge University Hospitals Expands Virtual Care Program with Masimo W1™

Masimo (NASDAQ: MASI) today announced that Cambridge University Hospitals NHS Foundation Trust, U.K. is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicin

May 08, 09:05

Aquyre Biosciences Announces Appointment of F. Samuel Eberts III as CEO and Chairman of the Board of Directors & Founder Bertrand de Poly as Chief Strategy & Technology Officer

Aquyre Biosciences, Inc. today announced the appointment of F. Samuel Eberts III as Chief Executive Officer and Chairman of its Board of Directors. Founder Bertrand de Poly will assume the role of Chi

May 07, 14:45

Kenvue to Begin Trading on the New York Stock Exchange

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will begin trading today on the New York Stock Exchange under the ticker symbol “KVUE” in connect

May 03, 14:00

SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares

Boehringer Ingelheim announced today that spesolimab (marketed as SPEVIGO®) received Breakthrough Therapy Designation (BTD) as an investigational treatment for the prevention of flares in adolescents

April 27, 11:45

New Point-of-Care Diagnostics Video from Nordson EFD Explains How Precise Fluid Dispensing Improves Production Accuracy

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new animated video focused on point-of-care diagnostic dispensing applications w

April 25, 09:30

MDimune Wins Bronze at 2023 Edison Awards

MDimune Inc., a biotech company developing BioDrone™ platform technology, has won the Bronze Award at the 2023 Edison Awards. The company has won in the Health, Medical & Biotech category for its next

April 23, 10:13

Dental Monitoring files a new claim against Get-Grin Inc. for patent infringement relating to its DM ScanBox device

Dental Monitoring has filed a lawsuit against Get-Grin Inc. (“Get Grin”) with the United States District Court for the District of Delaware alleging infringement of two of its patents (U.S. Patent Nos

April 20, 15:40

Aleph Farms Launches New Product Brand Aleph Cuts

Aleph Farms, a food technology company designing new ways to grow quality animal products, today announced the launch of its first product brand, Aleph Cuts. Under the Aleph Cuts brand, the company wi

April 19, 14:57

Augmented Reality: Patient Experience Trumps Misconceptions Around Injectables

New global research,[2] sponsored by Galderma and released today by leading filler brand Restylane®, has revealed the prevalent societal misconceptions and stereotypes facing the aesthetics industry.

April 19, 14:30

PCI Pharma Services Announces New Sterile Fill-Finish Capabilities Now Available in Melbourne and San Diego

PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced that three new state-of-the-art automated sterile fill-finish machines at its Sa

April 19, 11:10

Armis Announces Significant Business Momentum in Healthcare

HIMSS - Armis, the leading asset visibility and security company, today announced significant business momentum in the healthcare sector driven by healthcare and life sciences companies choosing the A

April 18, 17:07

Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health

Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health. BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals A/S

April 18, 10:10

KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO

KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, today announced the appointment of J.D. Mowery as Chief Executive Officer (CEO). Widely respected as an innovative biotech l

April 16, 15:18

AristaCare Health Services: The Future of Post-Acute Rehab and Long-Term Care

For over 20 years, AristaCare Health Services has been providing exceptional post-acute rehabilitation, memory care, and long-term care services to patients and residents in New Jersey and Pennsylvani

News by Region

News by Industry